Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
An oral therapeutic regimen of famotidine, a histamine H2-receptor antagonist, was evaluated in patients with chronic renal failure who were receiving dialysis three times a week. Measurements of the half-life, bioavailability, and dialysis elimination rate were performed. The half-life of famotidine after oral administration in patients with renal failure was 22.5 hours as opposed to 2.5 hours in control subjects: after intravenous injection, it was 14.6 hours as compared with 2.2 hours. The bioavailability after oral administration was 49.4% in patients with renal failure and 55.2% in control subjects. The dialysis elimination rate was stable and independent of its plasma level, with an average of 41.9%. The oral administration of famotidine (20 mg) immediately after dialysis (60 mg/week) was found optimal and safe. There were no significant side effects with this regimen.
Hachisu
T
T
Department of Surgery, Sakura National Hospital, Japan.
Yokoyama
T
T
Oda
Y
Y
Ando
K
K
Hattori
Y
Y
Yoshida
T
T
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000097:blood; D001682:Biological Availability; D004334:Drug Administration Schedule; D015738:Famotidine; D005260:Female; D006207:Half-Life; D006635:Histamine H2 Antagonists / Q000008:administration & dosage* / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013844:Thiazoles / Q000008:administration & dosage* / Q000097:blood
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D015738:Famotidine